Literature DB >> 81297

The longitudinal course of congenital rubella encephalitis in nonretarded children.

M M Desmond, E S Fisher, A L Vorderman, H G Schaffer, L P Andrew, T E Zion, F I Catlin.   

Abstract

The neurologic course of congenital rubella syndrome was traced in 29 nonretarded children to 9 to 12 years. During the first two years, manifestations involved abnormal tone and reflexes (69%), motor delays (66%), feeding difficulties (48%), and abnormal clinical behavior (45%). Hearing loss was documented in 76%. From three to seven years, poor balance, motor incoordination (69%), and behavioral disturbances (66%) predominated. Hearing losses increased to 86%. Currently, at 9 to 12 years, 25 have residua which include learning deficits (52%), behavioral disturbances (48%), poor balance (61%), muscle weakness (54%), and deficits in tactile perception (41%). Two additional children now have hearing loss. The encephalitic manifestations of congenital rubella syndrome are diverse. Overriding problems differ at each phase of childhood. Current deficits influence progress in educational and home environments. For these children, adequate intelligence alone does not guarantee academic success.

Entities:  

Mesh:

Year:  1978        PMID: 81297     DOI: 10.1016/s0022-3476(78)80892-0

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  3 in total

1.  Binding sites for rubella virus on erythrocyte membrane.

Authors:  P Mastromarino; S Rieti; L Cioè; N Orsi
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

Review 2.  Genetic Syndromes, Maternal Diseases and Antenatal Factors Associated with Autism Spectrum Disorders (ASD).

Authors:  Asher Ornoy; Liza Weinstein-Fudim; Zivanit Ergaz
Journal:  Front Neurosci       Date:  2016-07-06       Impact factor: 4.677

3.  Long-term outcomes of survivors of neonatal insults: A systematic review and meta-analysis.

Authors:  Dorcas N Magai; Eirini Karyotaki; Agnes M Mutua; Esther Chongwo; Carophine Nasambu; Derrick Ssewanyana; Charles R Newton; Hans M Koot; Amina Abubakar
Journal:  PLoS One       Date:  2020-04-24       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.